US 7,615,642 B2
	Therapeutic compounds
William Brown, Montreal (Canada); Ziping Liu, Montreal (Canada); Daniel Page, Montreal (Canada); Zena Qadoumi, Burnaby (Canada); Sanjay Srivastava, Montreal (Canada); Maxime Tremblay, Montreal (Canada); Christopher Walpole, Montreal (Canada); Zhong-yong Wei, Montreal (Canada); and Hua Yang, Montreal (Canada)
Assigned to AstraZeneca AB, Sodertalje (Sweden)
Filed on Apr. 16, 2007, as Appl. No. 11/735,528.
Claims priority of provisional application 60/745011, filed on Apr. 18, 2006.
Prior Publication US 2007/0244092 A1, Oct. 18, 2007
Int. Cl. A61K 31/4184 (2006.01); C07D 403/14 (2006.01)

U.S. Cl. 548—304.7  [514/394]

2 Claims

1. N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide or a pharmaceutically acceptable salt thereof.